文献速递肾移植

贝拉西普通过直接作用于B细胞及受损的Tfh-B细胞交互控制肾移植体液免疫

Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.
PubMed 文献 · J Am Soc Nephrol · 2018-01-10

肾移植后新生供体特异性抗体(dnDSA)是晚期移植物失败的主因。研究显示贝拉西普(CTLA4-Ig)在体外不依赖T细胞地减少浆母细胞分化、Ig产生及Blimp-1表达,并阻断CD28介导的Tfh活化;在肾移植受者中,贝拉西普治疗者血效应B细胞及活化Tfh(PD1+ICOS+)比例低于对照,提示其直接调节B细胞功能及B-Tfh交互。

要点

  • 贝拉西普直接抑制B细胞分化为浆母细胞并减少Ig产生。
  • 贝拉西普阻断CD28介导的Tfh活化,并降低B细胞CD86表达。
  • 贝拉西普治疗受者血效应B细胞和活化Tfh比例低于对照。

核心结论

  • 贝拉西普通过直接调节B细胞功能及B细胞-Tfh交互来控制肾移植后的体液免疫应答。

研究设计与样本

  • 体外实验分析贝拉西普对人B细胞和Tfh-记忆B细胞模型的作用,并在贝拉西普治疗的肾移植受者中验证。

主要发现

  • 体外贝拉西普不依赖T细胞地减少浆母细胞分化、Ig产生及Blimp-1表达。
  • 贝拉西普激活刺激B细胞中的STAT3并降低CD86表达。
  • 贝拉西普在自体Tfh-记忆B细胞模型中阻断CD28介导的Tfh活化。
  • 贝拉西普治疗受者血效应B细胞及活化Tfh(PD1+ICOS+)比例低于对照。

临床怎么用

  • 贝拉西普可能通过直接抑制B细胞和Tfh交互来减少dnDSA产生,支持其用于肾移植受者的体液免疫控制。

局限性

  • 机制结论主要基于体外实验和观察性验证,需进一步临床研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Generation of de novo donor-specific antibodies (dnDSAs) after renal transplant is recognized as the leading cause of late transplant failure. Hence, the optimal immunosuppressive strategies to limit dnDSA development need to be defined. Recent clinical trials using the novel costimulatory blockade agent CTLA4-Ig (Belatacept) have shown that kidney transplant recipients (KTRs) treated with Belatacept have better graft survival and function and a lower proportion of dnDSAs than control-treated KTRs. Mechanisms involved in the control of humoral responses by Belatacept remain to be investigated. Here, we analyzed the effect of Belatacept on different steps of the B cell-mediated response in humans. In vitro, Belatacept reduced plasmablast differentiation, Ig production, and the expression of the major transcription factor involved in plasma cell function, Blimp-1, in a T cell-independent manner. Moreover, Belatacept induced activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86. Additionally, Belatacept blocked CD28-mediated activation of T follicular helper cells (Tfhs) in an autologous Tfh-memory B cells model. We then validated these observations in KTRs treated with Belatacept, who had a reduced proportion of blood effector B cells and activated Tfh (PD1+ICOS+) compared with control-treated KTRs. Our in vitro and in vivo results suggest that Belatacept modulates B cell function directly and at the level of B cell-Tfh interaction. These mechanisms likely account for the optimal control of humoral responses observed in KTRs treated with Belatacept.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Leibler C, Thiolat A, Hénique C, et al. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. J Am Soc Nephrol. 2018. PMID: 29321143. doi:10.1681/ASN.2017060679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。